Cyclo(-RGDfK), CAS 161552-03-0

Product Description: Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM[1]. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface[2].

Applications: Cancer-programmed cell death

Formula: C27H41N9O7

Citations: ACS Appl Mater Interfaces. 2019 Jul 31;11(30):26648-26663. /Acta Biomater. 2021 Mar 9;S1742-7061(21)00152-5./Adv Healthc Mater. 2021 May 29;e2100304./Bioact Mater. 2021 Jan 7;6(7):2039-2057./Biochem Biophys Res Commun. 2023 May 23./Drug Deliv Transl Res. 2024 Mar 18./Engineering. 8 October 2020./Heliyon. 2024 July 02./Mater Today Nano. 2023 Nov 10, 100432./Mol Ther Nucleic Acids. 2021 Jan 9;23:797-810./Acs Biomater Sci Eng. 2023 Apr 24.

References: [1]Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95./[2]Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.

CAS Number: 161552-03-0

Molecular Weight: 603.67

Compound Purity: 98.0

Research Area: Cancer

Solubility: DMSO : 83.33 mg/mL (ultrasonic)/H2O : 50 mg/mL (ultrasonic)

Target: Integrin

• Artikelnummer: MEXHY-P0023-25
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P0023-25
• Green Labware: Nein
• Verpackungseinheit: 25 mg
• Mengeneinheit: STK